Jannelle Fukuji, PA
Medical · Federal Way, WANPI 1396014114
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Genentech USA, Inc. at 50.6% of the total. Reporting peaked in 2023 at $3,969 and has fallen 90.5% since, to $378 in 2025. Among medical clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 82 payments — averaging $78.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$3K
- AstraZeneca$1K
- Novartis$510
- Sanofi$350
- GSK$282
- Genentech, Inc.$190
- plus $494 from 9 others
What the payments were for
- Consulting fees$2,37537%
- Travel & lodging$74812%
- Food & beverage$3,19550%
- Education$1122%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 8 | $3,254 |
| AstraZeneca | 31 | $1,349 |
| Novartis | 7 | $510 |
| Sanofi | 15 | $350 |
| GSK | 8 | $282 |
| Genentech, Inc. | 2 | $190 |
| Biocryst US Sales Co., LLC | 1 | $110 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Alk-abello, Inc | 1 | $59 |
| Regeneron Healthcare Solutions, Inc. | 2 | $58 |
| Boehringer Ingelheim | 2 | $58 |
| LEO Pharma Inc. | 1 | $56 |
| ADMA Biomanufacturing LLC | 1 | $19 |
| Blueprint Medicines Corporation | 1 | $19 |
| Phadia US Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,430 in reported general payments places this provider in the 90th percentile of 457 medical providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $48,616 |
| XolairOmalizumab | 22 | $38,424 |
| Arnuity ElliptaFluticasone Furoate | 54 | $12,566 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $11,383 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $5,555 |
| Qvar RedihalerBeclomethasone Dipropionate | 14 | $5,434 |
| Wixela InhubFluticasone Propion/Salmeterol | 25 | $3,428 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 32 | $2,804 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 52 | $1,265 |
| Ipratropium Bromide | 50 | $1,146 |
| Montelukast Sodium | 57 | $718 |
| Azelastine Hcl | 18 | $566 |
| Prednisone | 17 | $28 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Arnuity Ellipta, Breo Ellipta | $282 | $72,564124 claims |
| Genentech, Inc.Xolair | $190 | $38,42422 claims |
| AstraZenecaSymbicort | $1,349 | $5,55516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 457 medical providers in Washington.
Other medical in Federal Way
- Sara WagnerFederal Way$4K
- Diana McFarlaneSeattle$95K
- Karissa SecoraTacoma$53K
- Tori FranklinLakewood$23K
- Salvador LopezYakima$17K
- Amy NelsonSeattle$15K
- Rebecca JohnsonSpokane$14K
- Jonathan CyphersBurien$13K
- Jonathan WhiteSeattle$13K
- Julia TaylorSpokane$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.